FDA panel backs Pfizer RSV vaccine for older Americans
Mar 01, 2023
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86%.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors
Feb 16, 2023
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
Recommended 2023 adult immunization schedule published
Feb 10, 2023
Changes include a new section relating to COVID-19 vaccines and the addition of a newly licensed vaccine for hepatitis B.
Overall increase seen in COVID-19 vaccine acceptance globally
Jan 11, 2023
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals were hesitant about booster doses.
COVID-19 vaccination bests natural immunity for cutting death, hospitalizations
Dec 28, 2022
Natural immunity, however, was tied to a lower incidence of new infection.
Pfizer plans to charge more than $100 per COVID-19 shot in 2023
Oct 24, 2022
People with Medicare or Medicaid and those with private health insurance likely would get the vaccine for free.
CDC panel: Add COVID-19 shot to routine vaccine schedule
Oct 21, 2022
An advantage to having COVID-19 shots on the vaccine schedule is that insurance providers typically will cover recommended vaccines.
Pollution tied to risk for serious COVID-19 despite vaccination
Oct 07, 2022
Exposures to PM2.5 and NO2 was linked to increased risk for COVID-19-related hospitalization, with and without adjustment for vaccination.
Bivalent mRNA-1273.214 elicits better response against omicron
Sep 27, 2022
A booster dose of mRNA-1273.214 elicits more neutralizing antibodies against omicron compared with mRNA-1273, the original Moderna vaccine, with no new safety concerns.